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Essentials
• HDL subclasses were studied in acute coronary syndrome (ACS).
• HDL2 from ACS patients have better antiplatelet potency than HDL from non ACS subjects.
• ACS remodels the antiplatelet properties of HDL subclasses.
• Oxidized polyunsaturated fatty acids content of HDL is modified by ACS.
Summary. Background: Although HDLs have antithrombotic effects by reducing platelet activation, the relationship between HDL levels and the risk of acute coronary syndrome (ACS) is unclear, as HDL particles are heterogeneous in composition and biological properties. Objective: To characterize the effects of HDL2 and HDL3 subclasses from ACS patients and non-coronary artery disease (CAD) subjects on platelet activation. Methods:
We measured platelet aggregation and ex vivo thrombus formation, analyzed signaling pathways by flow cytometry, and performed a targeted lipidomics analysis on HDL subclasses. Results: Analysis of human platelet aggregation in suspension, adhesion on von Willebrand factor and thrombus formation on collagen under arterial shear demonstrated that HDL2 from ACS patients had higher antiplatelet potency than HDL3 from ACS patients and HDL from non-CAD subjects. HDL binding to scavenger receptor class B type I was essential for this effect. A lipidomics analysis revealed that HDL2 from ACS patients had more oxidized polyunsaturated fatty acids (PUFAs). An inverse correlation between the concentrations of 9-hydroxyoctadecadienoic acid (9-HODE), 13-hydroxyoctadecadienoic acid (13-HODE), the eicosapentaenoic acid metabolite 18-hydroxyeicosapentaenoic acid (18-HEPE) and hydroxyeicosatetraenoic acid isomers in HDL2 and platelet aggregation was observed. This relationship was further demonstrated by the direct inhibitory effects of 18-HEPE, 9-HODE, 13-HODE, 17-hydroxydocosahexaenoic acid and 14-hydroxydocosahexaenoic acid on collagen-related peptide-induced platelet aggregation, indicating that oxidized PUFAs contribute to the antithrombotic effect of ACS HDL2. Conclusions:
Introduction
Many acute coronary syndromes (ACSs) are caused by the rupture of an atherosclerotic plaque and the subsequent formation of an occlusive thrombus. A low plasma HDL cholesterol (HDL-C) level has been proposed as a strong predictor of platelet-dependent thrombus formation [1] . HDL-C has the property of preventing platelet activation and aggregation [2, 3] . In the search for novel therapeutic options, increasing the total plasma HDL-C level has served as a central guide, but has failed to provide clinical benefits [4] [5] [6] . This disappointment may be explained by the highly heterogeneous HDL particle population, in terms of the biochemical dynamics of each subfraction, and the functional impact on the oxidative, inflammatory or apoptotic processes linked to atherosclerosis [7, 8] . Plasma HDL particles differ in density, size, and lipid/protein composition, and on the basis of their size and density, HDL particles are classified into two major subclasses: large, lipid-rich HDL2 particles, and small, protein-rich HDL3 particles [9] . The modification of the atheroprotective HDL functionality is a typical feature of cardiometabolic disease, reflecting alterations both in the proteome and in the lipidome [10, 11] , and may alter HDL particle interactions with their environment and especially with platelets, which play a key role in the etiology of ACS. To the best of our knowledge, no study has investigated the modulation of the antiplatelet properties of HDLs in ACS patients, particularly those of the HDL2 and HDL3 subclasses. Currently, HDL antithrombotic dysfunction in coronary artery disease (CAD) patients has only been evaluated on endothelial cells with respect to tissue factor expression and nitric oxide production [12] . Thus, the biological activities and the molecular mechanisms involved in HDL2 and HDL3 subclass-dependent antiplatelet aggregation effects remain to be identified.
In the present study, we compared the antiplatelet effects of HDL2 and HDL3 from ACS patients and non-CAD control subjects, and characterized the signaling pathways modulated by both HDL subfractions. Because the biological activities of HDLs may be linked to HDL lipidome oxidative modifications [10] , the contents of oxidized polyunsaturated fatty acids (PUFAs) in HDL subfractions was quantified with a targeted lipidomic approach, and the identified lipid candidates were tested on activated platelets. Overall, our data provide evidence that ACS remodels the antiplatelet function of HDL subclasses.
Materials and methods

Materials
Horm collagen from equine tendon was from Takeda (Linz, Austria), collagen-related peptide (CRP) was from the laboratory of R. Farndale (Cambridge, UK), von Willebrand factor (VWF) (Wilfactin; LFB Biomedicaments, Lille, France), thrombin receptor agonist peptide (TRAP) (14 mer), ADP and U46619 were from Sigma Aldrich (St Quentin Fallavier, France), and thrombin was from Stago BNL (Asni eres sur Seine, France). The antiphospho-Akt (Ser473) and the anti-phospho-p38-mitogenactivated protein kinase (MAPK) (Thr180/Tyr182) antibodies were from Cell Signalling Technology (Saint Quentin Yvelines, France), and the anti-scavenger receptor class B type I (SR-BI) antibody was from Novus Biologicals (Abingdon, UK). (AE)17-Hydroxydocosahexaenoic acid (17-HDoHE), 14-(S)hydroxydocosahexaenoic acid (14-HDoHE), (AE)18-hydroxyeicosapentaenoic acid (18-HEPE), (AE)13-hydroxyoctadecadienoic acid (13-HODE) and 9-hydroxyoctadecadienoic acid (9-HODE) were from Interchim (Montluc ßon, France).
Patient population
Blood samples were obtained from patients with ACS admitted to the Cardiology Department of Toulouse University Hospital. The study protocol was conducted according to the principles of the Declaration of Helsinki. ACS patients (men and women, n = 30) were recruited after hospital admission and during the first week after ACS; blood samples were collected before discharge. During the same period, subjects (men and women, n = 30) with high cardiovascular risk but without CAD were recruited in the Arterial Hypertension and Therapeutic Department of Toulouse University Hospital. Inclusion criteria were the presence of at least two cardiovascular risk factors (high blood pressure, dyslipidemia, active smoking [more than one cigarette per day], and type 2 diabetes), without any previous myocardial infarction or any coronary event, and a negative stress test result (maximum and negative treadmill test or stress echocardiogram or normal myocardial perfusion scintigraphy) or a normal recent coronary angiography (< 12 months) finding, without coronary stenosis greater than 20%. ACS patients and non-CAD subjects were matched on age.
HDL isolation and subfractionation
Fasting peripheral venous blood samples were collected by standard venipuncture. Plasma was recovered after centrifugation at 1100 9 g for 10 min in a Beckman (Villepinte, France) J-6B centrifuge, and stored at À 75°C. HDL isolation and subfractionation from smallvolume plasma samples was performed by sequential flotation microultracentrifugation, as previously described [13, 14] , with the addition of 10 lM butylated hydroxytoluene (BHT).
37°C. Platelet aggregation (3 9 10 8 platelets mL À1 ) was induced by different agonists (CRP 6 lg mL À1 , TRAP [16] . For quantification purposes, 5-hydroxyeicosatetraenoic acid-d8 was used as an internal standard.
Statistical analysis
Data were expressed as mean AE standard error of the mean of multiple experiments. Pearson's chi-square test was used to compare categorical variables. A non-parametric Mann-Whitney U-test or Student's t-test was used to compare two groups, and Wilcoxon or ANOVA tests were used to perform multiple comparisons with PRISM (GraphPad, San Diego, CA, USA). A P-value of < 0.05 was considered to be statistically significant.
Results
Study population characteristics
The baseline characteristics of ACS patients (n = 30) and non-CAD subjects (n = 30) are shown in Table 1 . Lipid profiles were similar between ACS patients and non-CAD subjects: triglycerides (P = 0.491), total cholesterol (P = 0.734), LDL cholesterol (P = 0.683), and HDL cholesterol (P = 0.756). There were no significant differences among the two populations in age, gender, diabetes, or dyslipidemia, which are known major risk factors for arterial thrombosis [17] . In addition, there were no significant differences in the medical treatments, non-CAD subjects showing high cardiovascular risk factors being recruited in the Arterial Hypertension and Therapeutic Department.
HDL2 and HDL3 from ACS patients inhibit platelet aggregation
We first assessed the effects of HDL2 and HDL3 from ACS patients and non-CAD subjects on the aggregation of platelets from healthy donors in response to physiologically relevant agonists. HDLs from healthy donors (25-500 lg mL À1 apolipoprotein A1 [ApoA1] showed dosedependent inhibition of CRP-induced platelet aggregation, with a significant effect at an ApoA1 level of ≥ 50 lg mL À1 (Fig. S1 ), which was in the range reported in previous studies [18] . Preincubation of platelets from healthy donors with HDL2 or HDL3 (50 lg mL
À1
ApoA1) from ACS patients or non-CAD subjects resulted in significant inhibition of platelet aggregation induced by CRP, which acts through glycoprotein (GP) VI, a platelet-specific receptor for collagen. HDL2 and HDL3 from non-CAD subjects showed an inhibitory effect as compared with the maximal aggregation induced by CRP (69.7% versus 79%, P < 0.001 for HDL2, and 70.9% versus 79%, P < 0.001 for HDL3) (Fig. 1A,B) . Interestingly, HDL subclasses from ACS patients had a stronger inhibitory effect than those from non-CAD subjects (48.5% versus 17.4%, P < 0.001 for HDL2, and 41.1% versus 15.7%, P < 0.001 for HDL3) or healthy donors. Considering the ACS patients group, HDL2 had a slightly inhibitory effect than HDL3 (48.5% versus 41.1%, P < 0.05).
No significant difference was found between HDL2 and HDL3 from non-CAD subjects (69.7% versus 70.9%, P = 0.88). To check whether the inhibition of platelet aggregation is a general phenomenon that is not restricted to CRP-induced platelet activation, we tested the effects of HDL2 and HDL3 on platelet aggregation induced by other relevant agonists. Both HDLs from ACS patients and HDLs from non-CAD subjects reduced platelet aggregation induced by the thromboxane A 2 analog U46619, fibrillar collagen, TRAP, and ADP, with, again, a stronger effect of HDLs from ACS patients. In contrast, platelet aggregation induced by 0.1 U mL À1 thrombin was not significantly affected by HDL2 and HDL3 ( Fig. 2A-E) . The difference observed between TRAP (acting through PAR1) and thrombin (acting through protease-activated receptor [PAR] 1 and PAR4) suggests that the inhibitory effect of HDL subclasses in vitro is less obvious when platelets are stimulated with a potent activator inducing robust intracellular signaling. The secretion of a-granules (assessed by CD62p surface expression) and dense granules (assessed by CD63 surface expression) induced by TRAP stimulation was reduced by HDL2 treatment (20.4% AE 10.5% inhibition for HDL2 from non-CAD subjects versus 61.3% AE 18.6% inhibition for HDL2 from ACS patients, P = 0.004), whereas the secretion induced by CRP was not affected (not shown). HDL-depleted plasma fractions from ACS patients had no effect on platelet aggregation, further indicating the specificity of action of the HDL particles (Fig. S2 ).
Platelet adhesion on VWF and thrombus formation on collagen under arterial shear are reduced by HDL2 and HDL3
The effects of HDL2 and HDL3 on platelet adhesion and thrombus formation were studied with an integrated microfluidic assay, in which whole blood is perfused over a fibrillar collagen matrix at arterial shear rates of 500 s À1 and 1500 s À1 [19] . As expected, control platelets efficiently formed thrombi on the collagen matrix at 500 s À1 shear, and incubation of blood with HDL2 significantly reduced platelet adhesion and thrombus growth (Fig. 3A) . After 120 s of perfusion, the inhibitory effect of HDL2 from ACS patients was more potent than that of HDL2 from non-CAD subjects (Fig. 3A,B) . HDL3 from ACS patients or non-CAD subjects also inhibited thrombus formation, but no significant difference was observed (Fig. 3C) . Moreover, at a higher shear rate (1500 s À1 ), both HDL2 and HDL3 reduced thrombus formation, with a significantly stronger effect of these HDL subpopulations isolated from ACS patients (Fig. S3A,B) . VWF is critical for capture of platelets to the subendothelial matrix at sites of vascular injury; when perfused on a VWF matrix, platelets undergo translocation and rolling, and form stationary adhesion contacts via integrin a IIb b 3 activation. Preincubation of blood from healthy donors with HDL2 or HDL3 from non-CAD and ACS patients significantly decreased platelet adhesion to VWF at a shear rate of 1500 s
; however, HDL2 and HDL3 from ACS patients remained more efficient than HDL subclasses from non-CAD patients (Fig. 4A-C) . At a higher shear rate (4000 s À1 ), only HDL2 from ACS patients significantly inhibited platelet adhesion to VWF (Fig. S3C,  D) . Overall, these data indicate that HDL2 from ACS patients significantly inhibits platelet thrombus formation on immobilized collagen at arterial wall shear rates, and decreases platelet adhesion on VWF at high shear rates.
The scavenger receptor SR-BI plays a major role in the platelet aggregation-inhibitory effect of HDL subclasses
The vascular protective effects of HDLs are known to be mediated by binding to specific cell surface receptors, such as SR-BI, expressed on the platelet surface [20] . To determine whether SR-BI is involved in the antiplatelet effect of HDL subclasses, we preincubated platelets with a specific SR-BI-blocking antibody. Neutralizing SR-BI significantly reduced the inhibitory effects of HDL2 and HDL3 on platelet aggregation (Fig. 5A) , whereas a control isotype antibody had no effect (Fig. S4A) . The SR-BI-blocking antibody was also able to reverse the inhibitory effect of HDLs on TRAP-induced platelet aggregation (Fig. S4B) . Several studies have shown that block lipid transport-1 (BLT-1) modulates SR-BI activity by impairing cholesterol exchange between the cell and HDLs [21] . Platelets were pretreated with BLT-1, but it failed to restore normal platelet aggregation, suggesting that the effect of HDL subclasses is primarily mediated by binding through ApoAI to SR-BI (Fig. 5B) .
To gain further insights into the mechanisms by which HDL subclasses modulate platelet function, we investigated the effects of HDL2 and HDL3 on the signal transduction pathways involved in platelet aggregation. HDL2 and, to a lesser extent, HDL3 from ACS patients induced a significant reduction in the phosphorylation of Akt Ser473 following CRP stimulation (Fig. S5A ). In contrast, CRP-induced phosphorylation of p38-MAPK was unaffected by HDL2 or HDL3 (Fig. S5B) . VASP phosphorylation at Ser157 via protein kinase A (PKA) and/or protein kinase G (PKG) correlates with reduced activation of integrin a IIb b 3 , F-actin remodeling, and platelet aggregation [22] . Measuring VASP phosphorylation is an indirect method for evaluating the effect of HDL subclasses on the cAMP concentration and, in turn, on PKA activity. The pretreatment of resting platelets with HDL2 from ACS patients significantly increased VASP phosphorylation on Ser157 (Fig. S5C ).
Increased levels of oxidized PUFAs in HDL2 from ACS patients are associated with platelet aggregation inhibition
HDLs are susceptible to oxidative modification, especially in atherogenic diseases, and accumulate oxidized phospholipids because of the presence of PUFA substrates [10, 23] . Moreover, hydroxylated conjugated linoleic acid isomers possess antithrombotic properties [24] . We used a targeted liquid chromatography-mass spectrometry (LC-MS)-based lipidomics approach to measure the concentrations of several hydroxylated fatty acids in HDL subclasses from the two groups. Total concentrations of hydroxyoctadecadienoic acid isomers (9-HODE and 13-HODE), 18-HEPE and hydroxydocosahexaenoic acid isomers (17-HDoHE and 14-HDoHE) derived from the peroxidation of linoleic acid, eicosapentaenoic acid and Effects of HDL2 and HDL3 subclasses from acute coronary syndrome (ACS) patients and non-coronary artery disease (CAD) subjects on platelet aggregation induced by various agonists. Human washed platelets from healthy donors (n = 6) were preincubated or not with 50 lg mL À1 apolipoprotein A1 and HDL2 or HDL3 from ACS patients (n = 7) or non-CAD subjects (n = 7) for 30 min at 37°C, and this was followed by stimulation with (A) the thromboxane A 2 analog U46619 (5 lM), (B) collagen (3.3 lg mL
), (C) thrombin receptor agonist peptide (TRAP) (25 lM), (D) ADP (10 lM), and (E) thrombin (0.1 U mL À1 ). Platelet aggregation was monitored with a multichannel aggregometer for 10 min. Results are expressed as maximal platelet aggregation inhibition (%), and are the mean AE standard error of the mean of seven independent experiments. *P < 0.05 and **P < 0.01 versus collagen-related peptide stimulation. The percentages of aggregation were 80% AE 6% in control platelets stimulated with U46619 (5 lM), 78% AE 1% in those stimulated with collagen (3.3 lg mL À1 ), 68% AE 1% in those stimulated with TRAP (25 lM), 29% AE 3% in those stimulated with ADP (10 lM), and 88% AE 5% in those stimulated with thrombin (0.1 U mL À1 ).
docosahexaenoic acid, respectively, were significantly higher in HDL2 from ACS patients than in HDL2 from non-CAD subjects (Table 2) . Although their concentrations tended to increase in HDL2 from ACS patients as compared with HDL2 from non-CAD subjects, there were no significant differences in the total concentrations of hydroxyeicosatetraenoic acid isomers, which are derived from the peroxidation of arachidonic acid. Additionally, the total concentrations of 18-HEPE and 9-HODE were significantly higher in HDL2 than in HDL3 from ACS patients ( Table 2) . We found an inverse correlation between the concentrations of 18-HEPE, 9-HODE, 13-HODE, 17-HDoHE and 14-HDoHE in HDL2 particles and the platelet aggregation response in a sample population including ACS patients and non-CAD subjects (Table 3) . For HDL3, no association between oxidized PUFAs and platelet aggregation could be observed (Table 4) . We then investigated the effects of 18-HEPE, 9-HODE, 13-HODE, 17-HDoHE and 14-HDoHE on CRP-activated platelets. The five oxidized PUFAs tested modestly but significantly inhibited platelet aggregation induced by CRP (Fig. 6A) . 9-HODE, as the most effective oxidized PUFA tested, significantly decreased platelet aggregation induced by low doses of CRP (Fig. 6B,C) . Altogether, these results strongly support the idea that hydroxylated fatty acids could be important biologically active lipids contributing to the enhanced antithrombotic effect of HDL2 particles.
Discussion
The antithrombotic activity of HDLs represents an important aspect of their vascular protective effects. Nowadays, it is accepted that the beneficial characteristics of HDLs, unrelated to their cholesterol content, could be explained by the composition and the functionality of HDL subclasses. We show for the first time that ACS remodels the antithrombotic function of HDL subclasses towards a superior antiplatelet effect than that of HDL subclasses from non-CAD subjects.
The analysis of human platelet aggregation in suspension, adhesion on VWF and thrombus formation on collagen matrix under arterial shear reveals that HDL2 from ACS patients has enhanced antiplatelet potency as ). DIOC 6 -labeled human platelets in heparin-anticoagulated whole blood from healthy donors (n = 6) were preincubated (30 min at 37°C) or not with 50 lg mL À1 apolipoprotein A1 and HDL2 (A) or HDL3 (C) from ACS patients (n = 7) or non-CAD subjects (n = 7), and then perfused through collagen-coated microcapillaries. (B) Representative images of platelet-covered surfaces at 0, 120 and 180 s are shown. Quantification of the surface area covered by platelets was performed at two surface locations with IMAGEJ. Data are presented as the mean AE standard error of the mean of seven independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control or #P < 0.05 for HDL2 from ACS patients versus HDL2 from non-CAD subjects. Scale bar: 10 lm. compared with HDL3 from ACS patients, and HDL2 and HDL3 from non-CAD subjects. Consistent with the inhibitory effect of HDLs on platelet aggregation in suspension, we found that thrombus formation on immobilized fibrillar collagen at arterial shear rates was significantly decreased by HDL2 from ACS patients. Under these conditions, platelets first interact with VWF bound to collagen fibers, allowing platelet rolling and interaction with collagen through binding to GPVI and integrin a 2 b 1 , leading to their firm adhesion and thrombus formation. As soon as 120 s of flow, HDL2 from ACS patients was more effective in inhibiting thrombus formation than HDL2 from non-CAD subjects. This effect is consistent with the modifications of signal transduction and the decrease in platelet aggregation following GPVI stimulation induced by HDL2 from ACS patients. Interestingly, we also found that HDL2 from ACS patients inhibited platelet adhesion on immobilized VWF at a normal arterial shear rate and at a high shear rate found in acute arterial occlusion. It is noteworthy that a recent report has shown the ability of HDLs to interfere with VWF self-association, which consequently reduces the length and thickness of VWF fibers [25] . Thus, HDLs modulate both the physical self-association of VWF under shear and the platelet adhesion response following VWF-GPIb-factor V (FV)-FIX interaction. Moreover, an inverse relationship between circulating VWF levels and HDL concentrations has been described in atherosclerotic patients [26] . Our study demonstrates the involvement of the platelet-expressed receptor SR-BI [20] in the antiplatelet effect of HDL subclasses. SR-BI is a functional receptor for HDLs and mildly oxidized HDLs [27] . Interestingly, our results are consistent with studies reporting that the decreased expression of SR-BI in atherosclerotic patients is inversely correlated with platelet aggregation [20] . Because HDLs represent a mixture of particles that differ in size, composition, and apolipoprotein content, its interaction with SR-BI might be influenced by these different parameters. We hypothesize that the most effective antiplatelet effect of HDL2 particles from ACS patients could be attributable to preferential binding to SR-BI, as was shown with reconstituted-HDL particles [28] . Our hypothesis is strengthened by the use of BLT-1, which is known to enhance the affinity of . (A, C) DIOC 6 -labeled human platelets in heparin-anticoagulated whole blood from healthy donors (n = 6) were preincubated (30 min at 37°C) or not with 50 lg mL À1 apolipoprotein A1 and HDL2 (A) or HDL3 (C) from ACS patients (n = 7) or non-CAD subjects (n = 7), and then perfused through VWF-coated microcapillaries under a shear rate of 1500 s À1 . (B) Representative images of platelet-covered surfaces at 0, 120 and 180 s are shown. Quantification of the surface area covered by platelets was performed at two surface locations with IMAGEJ. Data are presented as the mean AE standard error of the mean of seven independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 versus control; #P < 0.05 for HDL2 from ACS patients versus HDL2 from non-CAD subjects, and #P < 0.05 for HDL2 from ACS patients versus HDL2 from non-CAD subjects and HDL3 from ACS patients versus HDL3 from non-CAD subjects. Scale bar: 10 lm.
SR-BI for HDLs [21] , but which had no effect on HDLinduced platelet aggregation inhibition. However, as the treatment of platelets with the SR-BI-blocking antibody did not completely restore the initial aggregation response, we cannot rule out the involvement of other receptors, such as the apolipoprotein E (ApoE) receptor ApoER2/LRP8. The participation of ApoER2 in the antiplatelet effect of HDLs could also contribute to the stronger inhibition observed with HDL2 (ApoE-rich and ApoA1-rich) than with HDL3 (ApoE-poor and ApoA1-rich) [29, 30] . How HDL particles can decrease platelet reactivity remains unclear. Calkin et al. [3] have proposed that HDL particles act partly through reducing the cholesterol content of platelet membranes. Membrane cholesterol is important for lipid raft organization and, in turn, for the efficiency of platelet signaling in response to membrane receptor activation [31] . BLT-1 treatment did not prevent the HDL antiplatelet effect, suggesting that cholesterol transfer through SR-BI is not involved. Our results show that HDL2 and HDL3 from ACS patients modulate the phosphorylation of Akt, an important signaling pathway downstream of the collagen receptor GPVI [32, 33] , but do not affect p38-MAPK [34] . It is also noteworthy that only HDL2 from ACS patients promoted significant phosphorylation of VASP on Ser157. This phosphorylation is known to negatively regulate the F-actin remodeling properties of VASP, and to correlate with reduced activation of integrin a IIb b 3 and platelet aggregation [35] . Whether HDL2 from ACS patients can induce the activation of PKA, PKG, or protein kinase C, which have been shown to phosphorylate VASP on Ser157 [35] , remains to be established. Clearly, a better understanding of the ). Results are expressed as maximal platelet aggregation inhibition (%), and are the mean AE SEM of 10 independent experiments. Table 2 Oxidized polyunsaturated fatty acid (PUFA) concentrations in HDL2 and HDL3 subclasses from acute coronary syndrome (ACS) patients (n = 7) and non-coronary artery disease (CAD) subjects (n = 7) signaling mechanisms modulated by HDL subclasses in relation to their composition is needed, particularly in the context of developing new HDL-targeted therapies.
On the basis of previous studies reporting enhanced antiaggregatory properties of generated oxidized HDLs [34] or endogenous oxidized HDLs isolated from patients with abetalipoproteinemia [18] , we performed an LC-MS analysis of oxidized PUFAs in HDL2 and HDL3 particles. Despite having a similar cardiovascular risk factor profile, ACS patients had more oxidized lipids associated with their HDLs than non-CAD subjects, which corroborates previous results showing HDL composition alteration in patients at high cardiovascular risk [36] . The study of Valiyaveettil et al. [34] demonstrated that oxidized HDLs suppress platelet aggregation in response to thrombin, collagen and ADP through binding to SR-BI. On the other hand, addition of hypochlorite-oxidized HDLs to human platelets results in an immediate and transient increase in intracellular calcium levels, and increases in the surface expression of P-selectin and platelet aggregation [37] . The discrepancies observed could be explained by the nature of the oxidized HDLs used. Indeed, the antithrombotic effect of oxidized HDLs is induced by mild oxidation of HDLs that increases the negative charge of HDL particles and enhances their affinity for SR-BI. Conversely, potent oxidation of HDLs (phospholipids and proteins) transforms HDLs into CD36 ligands that may, rather induce, platelet activation.
We show an enrichment in oxidized fatty acids associated with HDL2 from ACS patients as compared with that from non-CAD subjects (HDL subclasses were isolated under identical conditions by ultracentrifugation). One possible explanation could be that HDL2 particles are more sensitive to oxidative modifications because they are lipid-rich [7] and contain less paraoxonase-1 activity than HDL3 particles [38] . HDL3 particles are described as being less susceptible to oxidative modification than HDL2 particles when they are compared on a total mass basis [39] . HDL oxidative modification leads to the generation of lipid peroxidation products that mostly originate from the degradation of polyunsaturated x6 fatty acids, arachidonic acid, and its precursor linoleic acid [36] . The presence of hydroxyoctadecadienoic acids and hydroxyeicosatetraenoic acid, which are either enzymatically or non-enzymatically generated, on HDLs suggests that lipid peroxidation takes place in response to both inflammation and enhanced oxidative stress occurring during coronary heart disease. The significant enrichment of 9-HODE and 13-HODE associated with HDL2 from ACS patients is in agreement with the antiplatelet effect of these conjugated linoleic acid isomers [24, 40] . Our findings are also in line with a study showing that increased concentrations of 9-HODE and 13-HODE were present in total HDLs from type 2 diabetes patients, and platelet aggregation inhibition via SR-BI [41] . Moreover, the increased level of 14-HDoHE associated with HDL2 from ACS patients correlates with data showing an inhibitory role on human platelet aggregation [42] . Although no effects on platelets have been described so far for the eicosapentaenoic acid metabolite 18-HEPE, recent data have shown its antiinflammatory role and a protective effect against maladaptive cardiac remodeling [43] .
The remodeling of HDLs during ACS has been investigated by replacing ApoA1 with serum amyloid A; proteome changes during the acute-phase response were demonstrated, with functional effects including cholesterol efflux capacity [44] . Our study is consistent with a previous study [45] showing that, in the early phase of ST-elevation myocardial infarction, HDL particle subpopulations show alterations in both the lipidome and the proteome that contribute to impaired cholesterol efflux and antioxidative activities.
In conclusion, we show for the first time that ACS induces remodeling of the HDL2 subclass associated with higher antithrombotic potential through SR-BI. Overall, our data illustrate the complexity of HDL particle composition, and suggest a physiological adaptation of HDL properties in ACS patients that may lead to a reduction in their platelet- Table 4 Correlation analysis between platelet aggregation and HDL3 oxidized polyunsaturated fatty acid (PUFA) concentrations from 14 subjects: acute coronary syndrome patients (n = 7) and non-coronary artery disease subjects (n = 7)
Oxidized PUFA Correlation coefficient (r) for platelet aggregation and HDL3 after CRP activation P-value dependent thrombotic risk. Functional HDL high-throughput assays that assess their structure-function relationships in health and disease, as well as after therapeutic interventions, would not only improve our knowledge of HDL subclass properties, but also point to new therapeutic strategies for cardiovascular diseases.
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M. Elbaz, B. Payrastre, and C. Vindis contributed to the conception and design of the study, and wrote the manuscript. N. Montee, C. Garcia, J. Faccini, and P. Le Faouder performed experiments and acquired data. J. Series, O. Meilhac, and A.-V. Cantero were involved in providing key materials and reagents. All authors read and approved the final manuscript. Fig. S1 . Dose-effect of HDL on CRP-induced platelet aggregation. Fig. S2 . Plasma fraction depleted in HDL has no effect on CRP-induced platelet aggregation. The effect of 9-HODE at 3 lg mL À1 was also tested on platelet aggregation induced by different doses of CRP (6, 3 or 1 lg mL À1 ). Platelet aggregation assessed with a turbidimetric method was monitored with a multichannel aggregometer for 10 min under stirring conditions (1000 r.p.m.) at 37°C. Results are expressed as area under the curve at 4 min, and are the mean AE standard error of the mean of six independent experiments. *P < 0.05 and **P < 0.01 versus CRP stimulation with the vehicle. (C) Representative aggregation traces illustrating the effect of 9-HODE on CRP-induced platelet aggregation at different doses. Fig. S3 . Effect of HDL2 and HDL3 subclasses from ACS patients and non-CAD subjects on platelet adhesion and thrombus formation under flow on collagen and VWF matrices. Fig. S4 . Role of SR-BI in the inhibitory effect of HDL2 from ACS patients on platelet aggregation induced by CRP or TRAP. Fig. S5 . Effect of HDL2 and HDL3 subclasses on Akt, p38-MAPK and VASP phosphorylation in CRP-stimulated platelets.
